FDA grants approval to first biosimilar for treatment of patients with breast, stomac

[News]

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).

More... (https://www.news-medical.net/news/20171204/FDA-grants-approval-to-first-biosimilar-for-treatment-of-patients-with-breast-stomach-cancers.aspx)